Literature DB >> 24681940

[Efficacy of rituximab for TAFRO syndrome, a variant type of multicentric Castleman's disease].

Takayuki Ozawa1, Satoru Kosugi, Maiko Kito, Mayu Onishi, Toru Kida, Soichi Nakata, Hironori Take, Shuichi Katagiri.   

Abstract

A 48-year-old woman was hospitalized because of severe thrombocytopenia, leg edema, and fever. Intravenous immunoglobulin therapy was administered, but no efficacy was obtained. Her bone marrow was dry-tap, and fibrosis was found in the biopsy specimens. A positron emission tomographic study showed FDG-avid lymphadenopathy and hepatomegaly. Biopsy specimens of axillary lymph nodes showed Castleman's disease-like findings. Since she then developed severe proteinuria and massive pleural effusion, steroid therapy was started, providing temporary relief of symptoms other than the thrombocytopenia. However, rapid worsening of her general condition prompted us to attempt rituximab as salvage therapy. The pleural effusion, edema, and proteinuria disappeared soon after starting rituximab administration. Platelet counts also normalized and fibrosis of the bone marrow showed amelioration. Recently, a variant of multicentric Castleman's disease, termed the TAFRO syndrome, has been proposed, and our patient's features fit the diagnosis of this syndrome. Rituximab might be considered as a therapeutic option in such cases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24681940

Source DB:  PubMed          Journal:  Rinsho Ketsueki        ISSN: 0485-1439


  14 in total

1.  Aggressive TAFRO syndrome with reversible cardiomyopathy successfully treated with combination chemotherapy.

Authors:  Shunichiro Yasuda; Keisuke Tanaka; Ayako Ichikawa; Ken Watanabe; Emi Uchida; Masahide Yamamoto; Kouhei Yamamoto; Daisuke Mizuchi; Osamu Miura; Tetsuya Fukuda
Journal:  Int J Hematol       Date:  2016-05-31       Impact factor: 2.490

2.  Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version.

Authors:  Yasufumi Masaki; Hiroshi Kawabata; Kazue Takai; Masaru Kojima; Norifumi Tsukamoto; Yasuhito Ishigaki; Nozomu Kurose; Makoto Ide; Jun Murakami; Kenji Nara; Hiroshi Yamamoto; Yoko Ozawa; Hidekazu Takahashi; Katsuhiro Miura; Tsutomu Miyauchi; Shinichirou Yoshida; Akihito Momoi; Nobuyasu Awano; Soichiro Ikushima; Yasunori Ohta; Natsue Furuta; Shino Fujimoto; Haruka Kawanami; Tomoyuki Sakai; Takafumi Kawanami; Yoshimasa Fujita; Toshihiro Fukushima; Shigeo Nakamura; Tomohiro Kinoshita; Sadao Aoki
Journal:  Int J Hematol       Date:  2016-03-18       Impact factor: 2.490

3.  Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report.

Authors:  Silvia Tedesco; Laura Postacchini; Lucia Manfredi; Gaia Goteri; Michele M Luchetti; Antonella Festa; Armando Gabrielli; Giovanni Pomponio
Journal:  Exp Hematol Oncol       Date:  2015-01-14

4.  TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature.

Authors:  Malorie Simons; Emmanuel Apor; James N Butera; Diana O Treaba
Journal:  Case Rep Hematol       Date:  2016-09-29

5.  Diffuse Large B-cell Lymphoma during Corticosteroid Therapy for TAFRO Syndrome.

Authors:  Eiko Ohya; Minoru Mizutani; Haruna Sakaguchi; Takao Sekine
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

Review 6.  Successful Treatment of TAFRO Syndrome with Tocilizumab, Prednisone, and Cyclophosphamide.

Authors:  Taku Kikuchi; Takayuki Shimizu; Takaaki Toyama; Ryohei Abe; Shinichiro Okamoto
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

7.  Two Cases of Thrombocytopenia, Anasarca, Fever, Reticulin Fibrosis/Renal Failure, and Organomegaly (TAFRO) Syndrome with High Serum Procalcitonin Levels, Including the First Case Complicated with Adrenal Hemorrhaging.

Authors:  Mizuho Nara; Atsushi Komatsuda; Fumiko Itoh; Hajime Kaga; Masaya Saitoh; Masaru Togashi; Yoshihiro Kameoka; Hideki Wakui; Naoto Takahashi
Journal:  Intern Med       Date:  2017-05-15       Impact factor: 1.271

8.  Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome.

Authors:  Hanako Tsurumi; Yoshihide Fujigaki; Tadashi Yamamoto; Risa Iino; Kei Taniguchi; Michito Nagura; Shigeyuki Arai; Yoshifuru Tamura; Tatsuru Ota; Shigeru Shibata; Fukuo Kondo; Nozomu Kurose; Yasufumi Masaki; Shunya Uchida
Journal:  Intern Med       Date:  2018-01-11       Impact factor: 1.271

9.  Tocilizumab-resistant TAFRO Syndrome Complicated by Type II Respiratory Failure.

Authors:  Tatsuya Aoki; Mikio Wada; Atsushi Kawashima; Kouichi Hirakawa; Akihiro Nagata; Keizo Kagawa
Journal:  Intern Med       Date:  2017-10-11       Impact factor: 1.271

10.  Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplements.

Authors:  Satoko Oka; Kazuo Ono; Masaharu Nohgawa
Journal:  Clin Case Rep       Date:  2018-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.